Trump says Iran war "close to over" amid hopes for more negotiations
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) provided business updates Wednesday, including details on its brilaroxazine development program for schizophrenia and its intellectual property strategy. The company currently trades at a market capitalization of just $10.97 million, with shares at $0.86—down 96% from their 52-week high of $23.20.
According to a press release statement, Reviva has filed a composition of matter patent application for a new form of brilaroxazine and is seeking an accelerated review process. The company stated that, if granted, this patent could extend commercial exclusivity for brilaroxazine potentially through 2046. Despite the stock’s significant decline over the past year, InvestingPro analysis suggests the company may be undervalued at current levels. An InvestingPro Tip notes that Reviva holds more cash than debt on its balance sheet, with liquid assets exceeding short-term obligations—providing financial flexibility as it advances its clinical programs.
Reviva is preparing to seek alignment with the U.S. Food and Drug Administration (FDA) to use the new form of brilaroxazine in its future new drug application. This would involve switching the active pharmaceutical ingredient and formulation in the planned second Phase 3 trial for schizophrenia, known as RECOVER-2. The company expects to receive feedback from the FDA by mid-2026.
Preparations for the RECOVER-2 trial are ongoing. Reviva anticipates initiating trial-related activities in the second quarter of 2026 and beginning patient enrollment in the United States in the third quarter. The company expects the study to be completed in the fourth quarter of 2027. The FDA has already cleared the protocol for this trial.
Reviva updated its risk factor disclosures, stating that its business is heavily dependent on the success of brilaroxazine, which is its only advanced product candidate. The company noted it currently has no products approved for commercial sale and highlighted several regulatory risks, including the possibility of additional Phase 3 trials, FDA requirements for further studies, and other uncertainties in the approval process. The company reported a loss per share of $5.48 over the last twelve months, and analysts do not anticipate profitability this year. Investors seeking deeper insights can access 14 additional InvestingPro Tips, along with comprehensive financial health scores and Fair Value analysis.
Reviva’s only other product candidate, RP1208, remains in the pre-clinical phase, and the company does not expect to allocate significant resources to its development in the near term.
This article is based on information disclosed in a press release statement and a recent SEC filing.
In other recent news, Reviva Pharmaceuticals Holdings, Inc. completed a public offering that raised approximately $10 million in gross proceeds. The company sold 6,666,667 shares of common stock or equivalents at $1.50 per share, along with Series G and Series H warrants, which are exercisable immediately. Concurrently, Reviva Pharmaceuticals announced a one-for-twenty reverse stock split, which will take effect on March 9, 2026. This adjustment will consolidate every twenty shares of common stock into one share, uniformly affecting all shareholders. Following these announcements, D. Boral Capital downgraded Reviva Pharmaceuticals from a Buy to a Hold rating. The downgrade was influenced by the company’s decision to implement the reverse stock split. These developments reflect Reviva Pharmaceuticals’ recent strategic financial maneuvers.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.